UNCY Unicycive Therapeutics, Inc.Stock Price & Overview
$0.54-0.02 (-3.85%)3:57 PM 11/28/23
NASDAQ | $USD | Post-Market: $0.58 +0.04 (+7.41%) 5:11 PM
People Also Follow
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.